NCT06644326View on ClinicalTrials.gov

A PK Study of IkT-148009 in Older and Elderly Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

August 17, 2024

Study Completion Date

August 27, 2024

Conditions
Healthy
Interventions
DRUG

100mg IkT-148009 Wet

100mg wet tablet formulation

DRUG

200 mg Itraconazole

2 100mg capsules

DRUG

100mg IkT-148009 Dry

100mg dry tablet formulation

DRUG

50mg IkT-148009 Wet

50mg wet tablet formulation

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors
All Listed Sponsors
lead

ABLi Therapeutics, Inc.

INDUSTRY